Compare Core and Main Inc (CNM) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core and Main Inc vs Davita Inc — how do they compare? Core and Main Inc trades at $46.18 (market cap $8.73B), while Davita Inc trades at $181.62 (market cap $11.38B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.
| CNM | DVA | |
|---|---|---|
Market Cap | $8.73B | $11.38B |
Sector | Technology | Health |
52-Week High | $66.98 | $240.96 |
52-Week Low | $42.37 | $103.87 |
Enterprise Value | $11.02B | $24.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core & Main (CNM) trades at $45.9, down 0.86% today, with a bullish technical signal despite near-term pressure. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.57 beating expectations of $0.534. Revenue reached $7.44B in 2025 with 5.87% net margin, while analyst consensus remains positive with 57% buy ratings. Recent news highlights institutional activity including California State Teachers Retirement System increasing its position by 22.3% in Q1 2026.
CNM presents a compelling investment case with robust profitability (23.73% ROE) and improving cash flow trends, though elevated debt levels and competitive pressures warrant caution. The stock's current valuation at 19.76 P/E appears reasonable given growth prospects, with technical support at $46 providing downside protection. Upside potential exists if the company maintains its earnings beat streak and executes on FY26 guidance of $7.8-7.9B revenue.
DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.
The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
